Characteristics of patients
| . | All . | IDH1R132 . | IDH2R140 . | IDH2R172 . |
|---|---|---|---|---|
| Patients | 319 (100) | 127 (40) | 135 (42) | 57 (18) |
| Age, median (IQR), y | 61 (52-67) | 61 (52-67) | 61 (50-67) | 62 (56-68) |
| Males | 164 (52) | 68 (54) | 74 (55) | 22 (39) |
| sAML | 16 (5) | 10 (8) | 4 (3) | 2 (4) |
| WBCs, median (IQR), ×109/L | 3.7 (1.6-23.8) | 4.5 (1.6-20.7) | 8.8 (2.3-31.6) | 1.8 (1.2-2.7) |
| Cytogenetics | ||||
| Normal | 198 (67) | 72 (63) | 98 (77) | 28 (52) |
| Complex | 11 (4) | 9 (8) | 2 (2) | 0 |
| Trisomy 8/8q | 31 (10) | 16 (14) | 10 (8) | 5 (9) |
| Monosomy 7 | 12 (3) | 10 (9) | 2 (2) | 0 |
| Trisomy 11/11q | 13 (4) | 3 (3) | 2 (2) | 8 (15) |
| Not available, n | 22 | 12 | 7 | 3 |
| ELN 2010 risk groups | ||||
| Favorable | 86 (29) | 38 (33) | 48 (37) | 0 (0) |
| Intermediate-1 | 112 (38) | 34 (29) | 50 (39) | 28 (52) |
| Intermediate-2 | 75 (25) | 25 (22) | 24 (19) | 26 (48) |
| Adverse | 24 (8) | 18 (16) | 6 (5) | 0 (0) |
| Not available, n | 22 | 12 | 7 | 2 |
| Trials | ||||
| ALFA-0701 | 58 (18) | 26 (20) | 21 (16) | 11 (19) |
| ALFA-0702 | 132 (41) | 54 (43) | 57 (42) | 21 (37) |
| ALFA-1200 | 129 (41) | 47 (37) | 57 (42) | 25 (44) |
| HSCT in CR1 | ||||
| Eligible patients* | 197 (62) | 69 (54) | 77 (57) | 51 (89) |
| HSCT performed | 71 (36) | 23 (33) | 28 (36) | 20 (39) |
| . | All . | IDH1R132 . | IDH2R140 . | IDH2R172 . |
|---|---|---|---|---|
| Patients | 319 (100) | 127 (40) | 135 (42) | 57 (18) |
| Age, median (IQR), y | 61 (52-67) | 61 (52-67) | 61 (50-67) | 62 (56-68) |
| Males | 164 (52) | 68 (54) | 74 (55) | 22 (39) |
| sAML | 16 (5) | 10 (8) | 4 (3) | 2 (4) |
| WBCs, median (IQR), ×109/L | 3.7 (1.6-23.8) | 4.5 (1.6-20.7) | 8.8 (2.3-31.6) | 1.8 (1.2-2.7) |
| Cytogenetics | ||||
| Normal | 198 (67) | 72 (63) | 98 (77) | 28 (52) |
| Complex | 11 (4) | 9 (8) | 2 (2) | 0 |
| Trisomy 8/8q | 31 (10) | 16 (14) | 10 (8) | 5 (9) |
| Monosomy 7 | 12 (3) | 10 (9) | 2 (2) | 0 |
| Trisomy 11/11q | 13 (4) | 3 (3) | 2 (2) | 8 (15) |
| Not available, n | 22 | 12 | 7 | 3 |
| ELN 2010 risk groups | ||||
| Favorable | 86 (29) | 38 (33) | 48 (37) | 0 (0) |
| Intermediate-1 | 112 (38) | 34 (29) | 50 (39) | 28 (52) |
| Intermediate-2 | 75 (25) | 25 (22) | 24 (19) | 26 (48) |
| Adverse | 24 (8) | 18 (16) | 6 (5) | 0 (0) |
| Not available, n | 22 | 12 | 7 | 2 |
| Trials | ||||
| ALFA-0701 | 58 (18) | 26 (20) | 21 (16) | 11 (19) |
| ALFA-0702 | 132 (41) | 54 (43) | 57 (42) | 21 (37) |
| ALFA-1200 | 129 (41) | 47 (37) | 57 (42) | 25 (44) |
| HSCT in CR1 | ||||
| Eligible patients* | 197 (62) | 69 (54) | 77 (57) | 51 (89) |
| HSCT performed | 71 (36) | 23 (33) | 28 (36) | 20 (39) |
Unless otherwise noted, data are n (%).
sAML, secondary AML; WBCs, white blood cells.
Patients with nonfavorable AML and not receiving gemtuzumab ozogamicin in ALFA-0701.